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aATE-BREAKING TRIALS
he Sudden Cardiac Death-Heart Failure Trial (SCD-
eFT) presented by Bardy et al. (1) included 2,521 patients
nrolled between September 1997 and July 2001 and fol-
owed until October 2003. Patients had to be on optimal
edical therapy and have New York Heart Association
NYHA) functional class II or III congestive heart failure
CHF) with an ejection fraction (EF) of 35%. The
atients were then randomized to either: 1) conventional
herapy for heart failure (HF) plus placebo, 2) conventional
herapy for HF plus amiodarone, or 3) conventional therapy
or HF plus the implantable cardioverter-defibrillator
ICD). The patients’ median age was 60 years, with 23%
eing female and 23% minorities. The median EF was 25%,
ith 70% of patients being NYHA functional class II and
0% being class III. Fifty-two percent of patients had
schemic cardiomyopathy, and 48% had non-ischemic car-
iomyopathy. Patients received excellent medical therapy,
ith 85% of them on angiotensin-converting enzyme
ACE) inhibitors and 69% of patients taking beta-blockers.
he average follow-up was 2.5 years, with 3-year mortality
eing 22% in the placebo group, 24% in the amiodarone
roup, and 17% in the ICD group. Table 1 shows the
azard ratios for each group, with a significant benefit from
he ICD versus placebo in all patients and in the separate
roups of ischemic and non-ischemic cardiomyopathy.
Amiodarone did no better than placebo. This study is the
rst to support use of the ICD as primary therapy for the
revention of sudden cardiac death in patients with mod-
rate to severe HF and non-ischemic dilated cardiomyopa-
hy; it also supports the results of the COmparison of
edical therapy, Pacing ANd defibrillatION in chronic
eart failure (COMPANION) trial in ischemic and non-
schemic cardiomyopathy and backs the findings of Multi-
enter Automatic Defibrillator Implantation Trial (MA-
IT II) in patients with ischemic cardiomyopathy. This
tudy suggests that amiodarone use in patients with well-
anaged CHF does not decrease mortality.
The Defibrillator IN Acute Myocardial Infarction Trial
DINAMIT) presented by Hohnloser et al. (2) enrolled 674
atients within 4 to 40 days of myocardial infarction (MI)
ith an EF of35% and impaired autonomic tone assessed
y heart rate variability. Patients were randomized to either
CD (332 patients) or control (342 patients) and followed a
ean of 2.5 years. The average EF was 28%, and the ICD
as implanted a median of seven days following MI.
ixty-five percent of patients received reperfusion therapy,pFrom the Mayo Clinic, Rochester, Minnesota.ore than 90% were on ACE inhibitors and beta-blockers,
nd more than 70% were on lipid-lowering drugs. The
azard ratios of ICD versus control were as follows: all cause
ortality 1.08; arrhythmic death 0.42; and non-arrhythmic
eath 1.75. The ICD significantly reduced the incidence of
rrhythmic death but, of interest, was associated with an
ncreased incidence of non-arrhythmic death. These pa-
ients had a high percentage use of intra-aortic balloon
ump to support circulation early after a major anterior wall
I. This study helps to identify the proper timing for ICD
lacement after MI.
The Prospective Randomized Study Evaluating Biven-
ricular Pacing After Ablate and Pace Therapy (PAVE) trial
resented by Doshi et al. (3) enrolled 165 patients with
trioventricular (AV) nodal ablation for atrial fibrillation.
atients were randomized 2:1 to biventricular (BiV) versus
ight ventricular pacing. The mean age was 68 years, with
5% of patients having NYHA functional class I to III
HF. The mean EF was 45%. These patients were followed
or six months. Biventricular pacing was associated with a
tatistically significant benefit over right ventricular pacing
n 6-min walk (26-m gain), quality of life (on the Short
orm-36), and peak oxygen consumption (1 ml/kg/min
ain).
ASIC STUDIES IN CARDIAC ARRHYTHMIAS
n important study by Hong et al. (4) reported on two
amilies with the short QT syndrome (QT interval 210 to
70 ms) and a strong family history of sudden unexpected
eath. A missense mutation was identified that resulted in
n amino acid change in the pore-forming region of the Kr
hannel (KCNH2 HERG). This leads to heterogeneous
bbreviation of the action potential duration and refracto-
iness, creating a potential re-entry substrate.
A second basic study of interest was reported by Wolf et
l. (5) evaluating myotonic dystrophy in transgenic mice.
yotonic dystrophy is caused by a CTG trinucleotide
xpansion on chromosome 19. Their study showed that
arger CTG expansions were associated with a higher risk of
onduction disease.
ULMONARY VEIN ISOLATION
OR TREATING ATRIAL FIBRILLATION
he long-term efficacy of pulmonary vein isolation (PVI) in
67 patients with paroxysmal atrial fibrillation (AF) was
ompared with 20 patients with persistent AF in a study by
ral et al. (6). As a group, 11% of patients required a repeat
blation and 2% had complications but no symptomatic
ulmonary vein stenosis. During two years of follow-up,
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ompared with 25% of patients with persistent AF. A
econd study comparing the outcome of PVI in patients
ith normal hearts (194 patients) and those with heart
isease (183 patients) was reported by Khaykin et al. (7).
eart disease was defined as an EF under 40%, presence of
alvular heart disease, or prior coronary artery bypass graft-
ng. Patients were followed for a mean of 16 months, with
.7% of patients having complications and 25% requiring a
econd PVI. As a group, 85% of patients were free from AF
t last follow-up, showing no significant difference in
utcome between patients with normal hearts and those
ith heart disease. These studies stress the changing ap-
roach to treating patients with AF by PVI. It appears that
blating a wider circumference around the pulmonary veins
chieves excellent outcome both in patients with otherwise
ormal hearts and patients with associated heart disease.
dvanced surgical and catheter ablation for cardiac
rrhythmias. A study by Vigilance et al. (8) sought to
nswer whether or not a linear line between the circumfer-
ntial ablation around the left pulmonary veins (PVI) and
he mitral valve was important in preventing postoperative
F in patients undergoing surgical ablation to treat their
F. They found no difference in the incidence of postop-
rative AF (67%) or atrial flutter by comparing the 118
atients who had PVI plus a connecting mitral valve lesion
o the 69 patients who had only the PVI. An interesting
tudy by Ernst et al. (9) reported on a new magnetic catheter
avigation system guided through a joy-stick, which posi-
ions the catheter tip. Patients were treated with radiofre-
uency ablation for re-entry within the AV node, counter-
lockwise atrial flutter, AV re-entry tachycardia, and atrial
achycardia. The investigators reported a success rate of
95% with no complications and requiring only a mean of
2.3 min of fluoroscopy time. The procedures included a
etrograde aortic approach in three patients and a trans-
eptal approach to the left atrium in another three patients.
A report from Omran et al. (10) of 20 patients treated
ith a percutaneous left atrial occlusion device to prevent
hromboembolism associated with chronic AF showed no
erebral emboli by magnetic resonance imaging scanning
nd no thrombus on the occlusion device at 12 months of
ollow-up in the absence of anticoagulation. This important
tudy demonstrates the safety of this new procedure as an
able 1. Sudden Cardiac Death-Heart Failure Trial, Average
ollow-Up 2.5 Years
ICD vs.
Placebo
Amiodarone vs.
Placebo
ll patients 0.77 1.05
schemic cardiomyopathy 0.79 1.08
on-ischemic cardiomyopathy 0.73 1.07
ata presented are hazard ratios. Source: Bardy and associates for the SCD-HeFT
nvestigators.
ICD  implantable cardioverter-defibrillator.lternative approach to preventing thromboembolic eventsn patients with chronic AF who are not candidates for
nticoagulation.
ardiac resynchronization therapy. The question of
hether or not AV delay optimization benefits patients with
ardiac resynchronization therapy (CRT) was reported in a
tudy by Kedia et al. (11). They did AV delay optimization
sing Doppler echocardiography and Ritter methods within
hree months of CRT implantation in 116 patients. The
nal settings were changed in only 22% of patients. This
uggests that the initial settings at the time of implantation
f the CRT device were adequate in the majority of patients
nd they did not benefit by routinely scheduled optimization
ithin three months of implantation. Seidle et al. (12)
eported on CRT in patients with central sleep apnea and
howed that CRT significantly improved sleep-related
reathing disorders. A study by Bhargava et al. (13) reported
hat comparable improvement in EF was observed in
atients treated with CRT using either a transvenous
oronary sinus lead or an epicardial left ventricular lead.
his study indicates that patients who would benefit from
RT and in whom a coronary sinus lead cannot be placed
hould proceed with BiV pacing using a left ventricular
picardial lead.
In summary, the American College of Cardiology (ACC)
cientific Sessions for 2004 helped to define which patients
enefit from an ICD as primary prevention therapy for
ife-threatening ventricular arrhythmias. The importance of
VI to treat patients with AF was a highlight of the 2004
ignificant sessions. Application of this technique is being
xtended to patients with associated heart disease, and the
ncidence of serious complications is decreasing in the
arger, more recent series. Further understanding for CRT
as presented during the session.
eprint requests and correspondence: Dr. Stephen C. Hammill,
ayo Clinic, Gonda SLW, Room 33S, Rochester, Minnesota
5905-0001. E-mail: hammill.stephen@mayo.edu.
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